OOIR: Observatory of International Research

Papers

(The TQCC of Expert Review of Pharmacoeconomics & Outcomes Research is 4. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)

Article	Citations
How to create value with constrained budgets in oncological care? A narrative review	48
Direct medical and indirect absenteeism costs among working adult ADHD patients in the United States	46
The value of cycleways to improve population physical activity levels: a systematic review of economic evaluations	39
The impact of changing the funding model for genetic diagnostics and improved access to personalized medicine in oncology	38
Cost per responder analysis of lebrikizumab versus tralokinumab in moderate to severe atopic dermatitis from a United States perspective	35
Indication-based pricing of the pharmaceuticals in Croatia: case-study	23
Economic value of knowing BRCA status: BRCA testing for prostate cancer prevention and optimal treatment	23
Engagement of medication users in the development and implementation of digital medication adherence technologies: a multi-stakeholder study	19
Cost-effectiveness of mechanical thrombectomy versus intravenous thrombolysis in acute ischemic stroke: a systematic review	17
Social care data in the UK; current landscape, challenges, and future recommendations	17
Adherence to augmentation therapy for the treatment of major depressive disorder	15
Clinical and economic impact analysis of viscosupplementation with hylan G-F 20 versus hyaluronic acids and no viscosupplementation for the treatment of knee osteoarthritis in Colombia	15
Consumption of antidepressants and economic austerity in Brazil	14
Direct diabetes-related healthcare expenditures in Slovenia: recent evolution and future projections based on population-level data	12
The impact of under-investment on health in Southern and Central Eastern European Countries	12
The role of insurance policies in the drug pricing landscape	12
Cost-effectiveness analysis of nivolumab-chemotherapy as first-line therapy for locally advanced/metastatic gastric cancer: a United States payer perspective	12
A projected cost-utility analysis of avacopan for the treatment of antineutrophil cytoplasmic antibody-associated vasculitis in Spain	12
A methodological guide for implementing and interpreting results of probabilistic analysis	12
Time from approval to reimbursement recommendations in healthcare systems with centralized HTA processes. Focus on the Polish HTA agency	12
Medication adherence research: expert perspectives on key HEOR trends for 2026	11
Cost-effectiveness comparison of dalpiciclib and abemaciclib combined with an aromatase inhibitor as first-line treatment for HR+/HER2− advanced breast cancer	11
Cost-effectiveness analysis of tofacitinib for the treatment of moderate to severe rheumatoid arthritis: a systematic review and meta-analysis	11
Cost effectiveness of non-pharmacological interventions for fatigue in patients with long-term conditions: a systematic literature review	10
International comparability of reference unit costs of education services: when harmonizing methodology is not enough (PECUNIA project)	10

The impact of bone turnover marker on medication adherence and the health economics-related consequences	10
Mapping of the health of the Nation Outcomes Scale (HoNOS) and Positive and Negative Symptom Scale (PANSS) to the EQ-5D-3L in psychosis patients using the PHAMOUS study	10
Cost-utility analysis of multiple sclerosis rehabilitation in Iran	9
Systematic reviews of machine learning in healthcare: a literature review	9
Cost-effectiveness analysis of pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric/gastroesophageal junction cancer in the Chinese healthcare system	9
Health and economic impact of 20-valent pneumococcal conjugate vaccine for adults aged 66–84 years in Japan and Shiga prefecture	9
Access to medicines, care, and services for multiple sclerosis patients in Central and Eastern European countries: a comparative analysis	9
Cost consequence minimization and budget impact model for introducing the fully liquid combined acellular hexavalent vaccine into the Dominican Republic’s expanded immunization plan	9
The economic burden of biologic disease-modifying antirheumatic drugs in rheumatoid arthritis patients in the United States	9
Valuing quality of life for economic evaluations in cancer: navigating multiple methods	9
Regulatory perspectives on post-market evidence generation schemes for high-risk medical devices: a systematic review	9
Pembrolizumab combined with chemotherapy versus placebo combined with chemotherapy for HER2-negative advanced gastric cancer in China: a cost-effectiveness analysis	9
Adherence to oral anticoagulants in patients with non-valvular atrial fibrillation: the role of patients’ characteristics and out-of-pocket payments	8
Cost-utility analysis of osimertinib and dacomitinib in the first-line treatment of advanced non-small cell lung cancer with EGFR mutation	8
Digital measures in epilepsy in low-resourced environments	8
Patients’ health related quality of life after massive weight loss reconstruction in the Netherlands	8
Economic value of toripalimab plus axitinib as first-line treatment for advanced renal cell carcinoma in China: a model-based cost-effectiveness analysis	8
Evaluation instruments for executive functions in children and adolescents: an update of a systematic review	8
Cost–utility analysis of dupilumab compared with endoscopic sinus surgery in patients with chronic rhinosinusitis with nasal polyps. Evaluation in Colombia, a developing country	8
Individual vs societal perspectives: implications on quantitative benefit-risk assessment of vaccination	8
Impact of patient’s financial burden of COVID-19 treatment on antiviral prescription rates and clinical and economic outcomes	7
The socioeconomic burden of cervical cancer and its implications for strategies required to achieve the WHO elimination targets	7
How relevant is the BMI for cost-of-illness studies in the 21st century?	7
Knowledge, perception and application of pharmacoeconomics among healthcare professionals in Malaysia	7
Are quality-adjusted life years (QALYs) becoming more expensive? Evidence from economic evaluations of diabetic therapeutics	7
Physician and patient adherence in hypertension trials: a point of view on an important issue to resolve	7
Economic evaluation of an add-on module to reduce intrusive suicidal mental images in patients with depressive symptoms	7
Cost of rimegepant and lasmiditan associated adverse events, for acute treatment in migraine in Spain	7
Systematic review on the use of cost-benefit analysis to evaluate food environment interventions	7
Intravenous and subcutaneous vedolizumab for moderately to severely active ulcerative colitis in Iran: a model-based cost-effectiveness evaluation	7
Qualitative research on the acceptance of evolving evidence for HTA body approval of innovative health technologies in selected European countries	7
Burden of illness among intermittent catheter users with non-neurogenic urinary retention in Denmark	7
Value elements and methods of value-based pricing for drugs in Japan: a systematic review	7
The pharmaceutical market: a transdisciplinary description of concepts and their implications	7
Real-world analysis of the economic and therapeutic burden in advanced breast cancer patients in Italy	7
Valuing prevention: lessons and recommendations from a Dutch expert committee	7
Developing the Lebanese health economic evaluation guideline	7
Timely access to new drugs in a single-payer system: policy analysis from South Korea’s reimbursement framework	6
Reimagining pharmacoeconomics in the age of artificial intelligence: opportunities, challenges, and future directions	6
Incorporating diagnostic testing into economic evaluations of tumour-agnostic therapies	6
Precision medicine in Thoracic Oncology: understanding disparities to tackle inequities in access	6
The potential public health impact of new immunization strategies for the prevention of RSV in children in Panama	6
Burden of disease of chronic pain in Ecuador	6
Transdisciplinary health economics for 2050: the challenge of preventing the adverse health effects of obesity, inequalities, and climate change	6
Economic analysis of cerliponase alfa for treatment of late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2)	6
Development and implementation of a stratified enhanced recovery after surgery pathway for ventral hernia repair	6
Cost-effectiveness of camrelizumab plus chemotherapy versus chemotherapy alone as first-line therapy in advanced or metastatic esophageal squamous cell carcinoma	6
Management of low back pain in the Brazilian public health system: budget impact analysis of the implementation of Pilates exercises compared to usual care	6
Bridging the gap: enhancing medication adherence through research and innovation	6
Economic and humanistic burden of chronic liver diseases in the United States	6

Mapping the World Health Organization Disability Assessment Scale 2.0 to the EQ-5D-5L in patients with mental disorders	6
A retrospective observational analysis of the real-world care pathway of people with hereditary transthyretin amyloidosis with polyneuropathy in Italy	6
A cost analysis of a simplified model for HCV screening and treatment at a tertiary hospital in Zimbabwe	5
Economic benefits of global Collaborative Health technology	5
Using natural language processing to analyze unstructured patient-reported outcomes data derived from electronic health records for cancer populations: a systematic review	5
Healthcare costs, resource utilization, and productivity loss associated with colorectal cancer screening	5
Work absenteeism, disability, and lost wages among patients with acute myeloid leukemia and their caregivers: a cohort study using US administrative claims and productivity data	5
Tenecteplase in managing acute ischemic stroke: a long-term cost–utility analysis in Iran	5
Determination of the economically justifiable price of cenobamate in the treatment of focal-onset seizures in adult patients with drug-resistant epilepsy in Spain	5
Adherence to asthma and COPD inhaled therapies in low- and middle-income countries: a narrative review	5
Preferences of people with diabetes for diabetes care in Germany: a discrete choice experiment	5
A comprehensive measurement of hemophilia economic burden in Iraq: a field-based study	5
Methodological standards for comparative effectiveness research: considerations for evidentiary review for medicare drug price negotiation	5
Budget impact analysis of transurethral water vapor therapy for treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia in the Spanish national healthcare system	5
Clinical and economic outcomes associated with intravenous albumin fluid use in the intensive care unit: a retrospective cohort study	5
Workplace productivity losses due to cancer: findings from an Australian longitudinal population survey (2009–2021)	5
Psychometric properties of outcome measures for freezing of gait in Parkinson’s disease: a systematic review and meta-analysis	5
The hidden burden of atopic dermatitis in central and Eastern European countries	5
How do patients value features of biological medicine in rheumatoid arthritis? A discrete choice experiment	5
Public value judgments about the criteria for reimbursement of medicines in South Korea	4
Improved medication adherence in COPD patients using tiotropium or tiotropium olodaterol with the HealthPrize digital behavior change program	4
Inebilizumab for neuromyelitis optica spectrum disorders in Italy: a budget impact model	4
Perceptions of risk sharing agreements in South Korea from the viewpoints of key stakeholders: a convergent parallel mixed approach	4
Value assessment of new interventions for Alzheimer’s disease dementia in Japan based on literature review and group interview	4
Costs for global guideline-based diagnosis of mucormycosis in patients with neutropenia, hematopoietic stem cell, or solid organ transplantation – a perspective of the German healthcare system	4
Use of machine learning to predict bladder cancer survival outcomes: a systematic literature review	4
Cost-effectiveness of HIV prevention interventions in sub-Saharan Africa (2019–2025): a systematic review	4
Pharmaceutical innovativeness index: methodological approach for assessing the value of medicines – a case study of oncology drugs	4
The Lebanese health economic evaluation guideline	4
A roadmap for applying machine learning when working with privacy-sensitive data: predicting non-response to treatment for eating disorders	4
Perspectives in prospective comparative economic evaluations: a systematic review	4
The short-term impact of copayment reductions for government subsidised medicines in Australia	4
Negating the burden of hip fracture in high-risk populations: a narrative review of epidemiology, costs, and multifaceted mitigation strategies	4
Healthcare resource utilization and associated costs in patients with metastatic castration-resistant prostate cancer in Greece	4
Cost-utility of sintilimab plus chemotherapy vs chemotherapy as first-line treatment of advanced gastric or gastroesophageal junction cancer in China	4
The economic impact of pharmacist intervention during pandemics	4
Digital decision aids and prenatal outcomes: a systematic review and meta-analysis	4
Cost-effectiveness analysis of cenobamate for epilepsy patients with drug-resistant focal onset seizures in the Netherlands	4
Secondary healthcare resource utilization and related costs associated with influenza-related hospital admissions in adult patients, England 2016 – 2020	4
Implementing a Managed Entry Agreement Framework in Cyprus	4
Evaluating reporting of patient-reported outcomes in peptic ulcer disease: a meta-epidemiological study of randomized controlled trials	4
Economic burden of cervical cancer and premalignant lesions associated with human papilloma virus: a societal perspective	4
Capturing the holistic value of biosimilars in Europe – part 1: a historical perspective	4
Correction	4
Trastuzumab deruxtecan versus chemotherapy treated in patients with HER2-positive metastatic breast cancer: a cost-effectiveness analysis based on the DESTINY-Breast02 trial	4
Cost-effectiveness of toripalimab plus chemotherapy versus chemotherapy as first-line treatment for advanced non-small cell lung cancer in China: a societal perspective	4
Value-based health care in Western countries: a scoping review on the implementation of patient-reported-outcomes sets for hospital-based interventions	4
The economics of prevention and quality of care: policy insights from the EU’s COVID-19 response	4
Enhancing pharmacist intervention targeting based on patient clustering with unsupervised machine learning	4
The impact of comprehensive public hospital reform on economic burden of inpatients with chronic obstructive pulmonary disease: evidence from a pilot city in western China	4
The value of functional genomics: a contingent valuation	4